Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia

Chimeric antigen receptor T (CAR-T) cells targeting CD19 have achieved great clinical responses in patients with relapsed or refractory (R/R) acute B lymphoblastic leukemia. However, severe adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yinqiang, Zhou, Fen, Wu, Zhuolin, Li, Yingnan, Li, Chenggong, Du, Mengyi, Luo, Wenjing, Kou, Haiming, Lu, Cong, Mei, Heng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253384/
https://www.ncbi.nlm.nih.gov/pubmed/35799791
http://dx.doi.org/10.3389/fimmu.2022.914959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253384/
https://www.ncbi.nlm.nih.gov/pubmed/35799791
http://dx.doi.org/10.3389/fimmu.2022.914959

Ejemplares similares